← All trials
NCT07221578
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 22, 2025
- Primary completion
- Dec 31, 2026
- Completion date
- Apr 30, 2027
- First posted
- Oct 28, 2025
- Last posted
- Nov 12, 2025
- Enrollment
- 500
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vanda PharmaceuticalsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.